Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1998-8-17
|
| pubmed:abstractText |
We examined the efficiency of disease-specific "standard" chemotherapies epirubicin, cyclophosphamide (EC); cyclophosphamide, vincristine, doxorubicin, etoposide, prednisolone (CHOEP); epirubicin, ifosfamide (EPI/IFOS) for peripheral blood progenitor cell (PBPC) mobilization in comparison to well-characterized mobilization protocols, i.e. etoposide, ifosfamide, cisplatin, epirubicin (VIPE) and dexamethasone, carmustine, etoposide, cytarabine, melphalan (DexaBEAM). Twenty-seven patients with various malignancies underwent 75 apheresis procedures for PBPC collection. Median cell yields from all 75 aphereses were 1.18 x 10(5) mononuclear cells/kg [range (0.28-3.7) x 10)8)], 1.4 x 10(5) granulocyte/macrophage-colony-forming units (CFU-GM)/kg [range (0.2-11) x 10(5)] and 3.3 x 10(6) CD34+cells/kg [range (0.35-17.7) x 10(6). CD34+/ CD90+ cells could be mobilized by all mobilization regimens used. The difference observed in the mobilization of CD34+ cells was only of low significance when the mobilization regimens were compared, whereas the mobilizations of MNC and CFU-GM were significantly different between the groups. Breast cancer patients treated with the VIPE regimen (including pretreated women) had a significantly higher CFU-GM rate than patients treated with EC (P=0.0005). Mobilized CD34+ PBPC were correlated with CFU-GM in all apheresis products. The linear correlation coefficients differed for the various mobilization groups: DexaBEAM (r=0.9, P < 0.0001), VIPE (r=0.68, P=0.0024), CHOEP (r=0.52, P=0.022), EPI/ IFOS (r=0.34, P=0.11) and EC (r=0.23, P=0.2). We conclude that clonogenic assays can provide additional information about the autotransplant quality, particularly when alternative or new mobilization regimens are being investigated.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Carmustine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0171-5216
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
124
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
341-5
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:9692843-Antigens, CD34,
pubmed-meshheading:9692843-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9692843-Blood Component Removal,
pubmed-meshheading:9692843-Carmustine,
pubmed-meshheading:9692843-Cell Separation,
pubmed-meshheading:9692843-Cyclophosphamide,
pubmed-meshheading:9692843-Cytarabine,
pubmed-meshheading:9692843-Dexamethasone,
pubmed-meshheading:9692843-Doxorubicin,
pubmed-meshheading:9692843-Epirubicin,
pubmed-meshheading:9692843-Etoposide,
pubmed-meshheading:9692843-Female,
pubmed-meshheading:9692843-Flow Cytometry,
pubmed-meshheading:9692843-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9692843-Granulocytes,
pubmed-meshheading:9692843-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:9692843-Hematopoietic Stem Cells,
pubmed-meshheading:9692843-Humans,
pubmed-meshheading:9692843-Ifosfamide,
pubmed-meshheading:9692843-Macrophages,
pubmed-meshheading:9692843-Male,
pubmed-meshheading:9692843-Melphalan,
pubmed-meshheading:9692843-Neoplasms,
pubmed-meshheading:9692843-Prednisolone,
pubmed-meshheading:9692843-Vincristine
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
|
| pubmed:affiliation |
Department of Internal Medicine II, Oncology, Hematology, Endocrinology, Metabolic Diseases, Friedrich-Schiller-University, Jena, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|